News
ATHE
1.840
+7.60%
0.130
Weekly Report: what happened at ATHE last week (0219-0223)?
Weekly Report · 1d ago
Alterity Therapeutics drops on capital raise
Seeking Alpha · 3d ago
Vir Biotechnology, Community Health Systems among healthcare movers
Healthcare On the Move: Vir Biotechnology, Community Health Systems among healthcare movers. S&P 500 Health Care Sector +0.18% to 1716.2. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is + 0.33%.
Seeking Alpha · 3d ago
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 4d ago
Alterity Therapeutics Earlier Announced A Proposed Offering Of 285,087,720 Shares
Benzinga · 4d ago
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Barchart · 02/20 09:25
Weekly Report: what happened at ATHE last week (0212-0216)?
Weekly Report · 02/19 11:37
Weekly Report: what happened at ATHE last week (0205-0209)?
Weekly Report · 02/12 11:25
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Exicure (NASDAQ:XCUR) shares rose 55.5% to $0.87 during Tuesday's pre-market session. InVivo Therapeutics Hldg shares moved upwards by 46.41% in the same session. Madrigal Pharmaceuticals ( NASDAQ:MDGL) shares decreased by 15.9% during the session.
Benzinga · 02/06 13:06
Weekly Report: what happened at ATHE last week (0129-0202)?
Weekly Report · 02/05 11:34
Weekly Report: what happened at ATHE last week (0122-0126)?
Weekly Report · 01/29 11:22
Alterity Therapeutics Highlights Successes in MSA Research and Plans for Parkinson's Disease Trials in Shareholder Letter
Alterity Therapeutics is a biotechnology company that is developing treatments for neurodegenerative diseases. The company's lead clinical development candidate is ATH434, an orally administered agent to target the brain. The drug is being developed for Multiple System Atrophy, or MSA, a disease related to Parkinson's.
Benzinga · 01/22 12:29
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 01/22 12:06
Weekly Report: what happened at ATHE last week (0115-0119)?
Weekly Report · 01/22 11:27
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics is a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases. Preliminary Data from ATH434-202 Study Expected in 1H 2024. Study to complete in November 2024. ATH is based in Australia.
Barchart · 01/22 06:25
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 01/18 16:08
Weekly Report: what happened at ATHE last week (0108-0112)?
Weekly Report · 01/15 11:23
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 01/12 00:21
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.